Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Red Hat (RHT) Gears Up For Q4 Earnings: What's In The Cards?

Published 03/21/2019, 10:57 PM
Updated 07/09/2023, 06:31 AM

Red Hat Inc. (NYSE:RHT) is set to report fourth-quarter fiscal 2019 results on Mar 25.

We note that, on average, the company has delivered a positive earnings surprise of 8.7% in the trailing four quarters. In the last-reported quarter, Red Hat delivered positive earnings surprise of 10.3%.

Earnings increased 31.5% on a year-over-year basis, primarily driven by 13.2% growth in revenues, which totaled $846.8 million.

IBM Set to Acquire Red Hat

International Business Machines (NYSE:IBM) is set to acquire Red Hat for approximately $34 billion in cash.

The deal is expected to be completed in the latter half of 2019 through a combination of cash and debt. Consequently, Red Hat’s shareholders will obtain $190 per share in cash, reflecting approximately 62.8% premium over the $116.68 price on Oct 26, 2018.

Notably, the majority of Red Hat shareholders approved the transaction at a special stockholder meeting held on Jan 16, 2019.

The company’s stock has returned 23.4% in the past year, underperforming the 31.7% rally of the industry it belongs to.



Factors to Watch Out

Red Hat is likely to benefit from strong adoption of its emerging technologies that include Ansible, OpenShift and OpenStack in the to-be-reported quarter. In the last-reported quarter, Red Hat OpenShift and Red Hat Ansible Automation experienced strong customer growth, adding more than 100 customers.

Moreover, its expanding partner base that includes the likes of Hortonworks, Intel (NASDAQ:INTC), Dell, Google (NASDAQ:GOOGL) cloud platform, Microsoft (NASDAQ:MSFT) Azure and Amazon (NASDAQ:AMZN) Web Services (AWS) are the key catalysts. These partnerships are helping the company cross-sell cloud-based technologies across its customer base.

The company’s expanding portfolio is also noteworthy. During the fiscal fourth quarter, it announced the availability of Red Hat Ansible Tower 3.4. It also announced the availability of Red Hat CodeReady Workspaces, a Kubernetes-native, browser-based development environment, which enables smoother collaboration across the development team.

Red Hat Cloudforms 4.7, the latest version of the company’s highly-scalable infrastructure management tool, was also made available in the to-be-reported quarter.

We believe Red Hat’s portfolio strength will help in expanding customer base and eventually boost top-line growth. The Zacks Consensus Estimate for revenues and earnings is currently pegged at $8886.7 million and $1.01, respectively.

What Our Model Indicates

According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) along with a positive Earnings ESP has a good chance of beating estimates. Sell-rated stocks (Zacks Rank #4 or 5) are best avoided.

Red Hat has a Zacks Rank #3 and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.

Stocks to Consider

Here are a couple of stocks you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat.

Shaw Communications (NYSE:SJR) has an Earnings ESP of +1.10% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Akamai Technologies (NASDAQ:AKAM) has an Earnings ESP of +5.16% and a Zacks Rank #2.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



International Business Machines Corporation (IBM): Free Stock Analysis Report

Akamai Technologies, Inc. (AKAM): Free Stock Analysis Report

Shaw Communications Inc. (SJR): Free Stock Analysis Report

Red Hat, Inc. (RHT): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.